Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential

Sarissa Capital initiated a new 513,184-share position in Biohaven (NYSE:BHVN) in Q4, valued at $5.79M at quarter-end and representing 2.6% of its reportable U.S. equity AUM. Biohaven shares trade at $8.90, down ~70% over the past year, with a market cap of about $1.3B and a TTM net loss of $738.8M; the company finished 2025 with ~$322M cash and raised an additional $178.9M post-year-end. Recent FDA rejection and disappointing trial updates have materially hurt sentiment, but management is narrowing focus to late-stage programs (degrader platform and a Phase 2 obesity candidate) with a potential catalyst in H2 2026. The new position aligns with the fund's biotech tilt and is modest relative to Biohaven's market cap, so immediate market impact is likely limited; upcoming clinical readouts will drive near-term direction.

Analysis

Sarissa’s initiation looks like a classic event-driven buy: low-cost optionality on a clinical-stage story with a concentrated catalyst calendar. That profile attracts funds that tolerate high idiosyncratic volatility and looks for asymmetric returns from readouts or partnerships, which can create a semi-permanent bid during the run-up to data and a sharp unwind on negative news.

From a competitive-dynamics angle, a failure would free patient recruitment, investigator attention and CRO capacity to rival obesity/degrader programs, improving near-term operating leverage for better-funded peers. A clean positive readout, by contrast, increases acquirer optionality for an asset with a simplified development path, compressing the time-to-liquidity and forcing re-rating ahead of any full commercialization decision.

Key risks and timing: the next 3–12 months are binary—near-term DSMB/safety/secondary endpoint updates can move the stock in days; the pivotal obesity dataset expected later this year is the primary value inflection. Tail risks include an adverse readout or funding stress that precipitates a disorderly sell-off; that makes defined-loss, hedged constructions preferable to naked long equity if you want exposure to the upside without an unconstrained downside.

Key Decisions for Investors

• Long, defined-loss event bet: Buy BHVN Jan-2027 10/20 call debit spread sized to 0.5–1.0% NAV. Rationale: asymmetric upside into the H2 data window with max loss = premium. Hedge: short 0.5% NAV of XBI to remove sector beta. Target: 2.5–4x payoff if positive readout; stop-loss = full premium.
• Protected equity: Buy BHVN shares (pilot 0.5% NAV) and purchase 6–9 month puts ~25–35% below entry to the readout window. Rationale: capture upside rerating if results are positive while capping downside from trial failure or funding shock. Review position post-readout and reduce protections if partnership progress emerges.
• Pair / market-neutral event trade: Long BHVN Jan-2027 10/20 call spread vs short equal-dollar exposure to a small-cap biotech basket (e.g., XBI or a custom 8–12 name basket) sized to net out beta. Rationale: isolate idiosyncratic upside from BHVN’s catalyst while neutralizing sector volatility. Timeframe: roll or unwind after H2 2026 readout.
• Opportunity for long-biotech rotate: If BHVN outcome is negative, realloc a portion of capital (0.5–1% NAV) into higher-quality clinical names with positive sentiment (e.g., CYTK or NBIX) with 12–24 month horizons. Rationale: patient/CRO reallocation and capital re-cycling tends to benefit nearby mechanism peers; aim for 1.5–3x upside over 1–2 years.